119 related articles for article (PubMed ID: 31010716)
1. An in vitro functional assay to measure the biological activity of TB vaccine candidate H4-IC31.
Ming M; Bernardo L; Williams K; Kolattukudy P; Kapoor N; Chan LG; Pagnon A; Piras F; Su J; Gajewska B; Salha D; Gisonni-Lex L
Vaccine; 2019 May; 37(22):2960-2966. PubMed ID: 31010716
[TBL] [Abstract][Full Text] [Related]
2. Prevention of M. tuberculosis Infection with H4:IC31 Vaccine or BCG Revaccination.
Nemes E; Geldenhuys H; Rozot V; Rutkowski KT; Ratangee F; Bilek N; Mabwe S; Makhethe L; Erasmus M; Toefy A; Mulenga H; Hanekom WA; Self SG; Bekker LG; Ryall R; Gurunathan S; DiazGranados CA; Andersen P; Kromann I; Evans T; Ellis RD; Landry B; Hokey DA; Hopkins R; Ginsberg AM; Scriba TJ; Hatherill M;
N Engl J Med; 2018 Jul; 379(2):138-149. PubMed ID: 29996082
[TBL] [Abstract][Full Text] [Related]
3. A high ratio of IC31(®) adjuvant to antigen is necessary for H4 TB vaccine immunomodulation.
Aboutorabian S; Hakimi J; Boudet F; Montano S; Dookie A; Roque C; Ausar SF; Rahman N; Brookes RH
Hum Vaccin Immunother; 2015; 11(6):1449-55. PubMed ID: 25997147
[TBL] [Abstract][Full Text] [Related]
4. Flow cytometry: An efficient method for antigenicity measurement and particle characterization on an adjuvanted vaccine candidate H4-IC31 for tuberculosis.
He L; Su J; Ming M; Bernardo L; Chen T; Gisonni-Lex L; Gajewska B
J Immunol Methods; 2018 Jan; 452():39-45. PubMed ID: 29056527
[TBL] [Abstract][Full Text] [Related]
5. Safety and immunogenicity of the novel H4:IC31 tuberculosis vaccine candidate in BCG-vaccinated adults: Two phase I dose escalation trials.
Norrby M; Vesikari T; Lindqvist L; Maeurer M; Ahmed R; Mahdavifar S; Bennett S; McClain JB; Shepherd BM; Li D; Hokey DA; Kromann I; Hoff ST; Andersen P; de Visser AW; Joosten SA; Ottenhoff THM; Andersson J; Brighenti S
Vaccine; 2017 Mar; 35(12):1652-1661. PubMed ID: 28216183
[TBL] [Abstract][Full Text] [Related]
6. The tuberculosis vaccine H4:IC31 is safe and induces a persistent polyfunctional CD4 T cell response in South African adults: A randomized controlled trial.
Geldenhuys H; Mearns H; Miles DJ; Tameris M; Hokey D; Shi Z; Bennett S; Andersen P; Kromann I; Hoff ST; Hanekom WA; Mahomed H; Hatherill M; Scriba TJ; ; van Rooyen M; Bruce McClain J; Ryall R; de Bruyn G;
Vaccine; 2015 Jul; 33(30):3592-9. PubMed ID: 26048780
[TBL] [Abstract][Full Text] [Related]
7. A phase 1b randomized study of the safety and immunological responses to vaccination with H4:IC31, H56:IC31, and BCG revaccination in
Bekker LG; Dintwe O; Fiore-Gartland A; Middelkoop K; Hutter J; Williams A; Randhawa AK; Ruhwald M; Kromann I; Andersen PL; DiazGranados CA; Rutkowski KT; Tait D; Miner MD; Andersen-Nissen E; De Rosa SC; Seaton KE; Tomaras GD; McElrath MJ; Ginsberg A; Kublin JG;
EClinicalMedicine; 2020 Apr; 21():100313. PubMed ID: 32382714
[TBL] [Abstract][Full Text] [Related]
8. A comparison of antigen-specific T cell responses induced by six novel tuberculosis vaccine candidates.
Rodo MJ; Rozot V; Nemes E; Dintwe O; Hatherill M; Little F; Scriba TJ
PLoS Pathog; 2019 Mar; 15(3):e1007643. PubMed ID: 30830940
[TBL] [Abstract][Full Text] [Related]
9. Tuberculosis vaccine candidate: Characterization of H4-IC31 formulation and H4 antigen conformation.
Deshmukh SS; Magcalas FW; Kalbfleisch KN; Carpick BW; Kirkitadze MD
J Pharm Biomed Anal; 2018 Aug; 157():235-243. PubMed ID: 29866391
[TBL] [Abstract][Full Text] [Related]
10. Ag85B-ESAT-6 adjuvanted with IC31® promotes strong and long-lived Mycobacterium tuberculosis specific T cell responses in volunteers with previous BCG vaccination or tuberculosis infection.
van Dissel JT; Soonawala D; Joosten SA; Prins C; Arend SM; Bang P; Tingskov PN; Lingnau K; Nouta J; Hoff ST; Rosenkrands I; Kromann I; Ottenhoff TH; Doherty TM; Andersen P
Vaccine; 2011 Mar; 29(11):2100-9. PubMed ID: 21256189
[TBL] [Abstract][Full Text] [Related]
11. Multidimensional analyses reveal modulation of adaptive and innate immune subsets by tuberculosis vaccines.
Rozot V; Nemes E; Geldenhuys H; Musvosvi M; Toefy A; Rantangee F; Makhethe L; Erasmus M; Bilek N; Mabwe S; Finak G; Fulp W; Ginsberg AM; Hokey DA; Shey M; Gurunathan S; DiazGranados C; Bekker LG; Hatherill M; Scriba TJ;
Commun Biol; 2020 Oct; 3(1):563. PubMed ID: 33037320
[TBL] [Abstract][Full Text] [Related]
12. First-in-human trial of the post-exposure tuberculosis vaccine H56:IC31 in Mycobacterium tuberculosis infected and non-infected healthy adults.
Luabeya AK; Kagina BM; Tameris MD; Geldenhuys H; Hoff ST; Shi Z; Kromann I; Hatherill M; Mahomed H; Hanekom WA; Andersen P; Scriba TJ; ; Schoeman E; Krohn C; Day CL; Africa H; Makhethe L; Smit E; Brown Y; Suliman S; Hughes EJ; Bang P; Snowden MA; McClain B; Hussey GD
Vaccine; 2015 Aug; 33(33):4130-40. PubMed ID: 26095509
[TBL] [Abstract][Full Text] [Related]
13. A new tool for tuberculosis vaccine screening: Ex vivo Mycobacterial Growth Inhibition Assay indicates BCG-mediated protection in a murine model of tuberculosis.
Zelmer A; Tanner R; Stylianou E; Damelang T; Morris S; Izzo A; Williams A; Sharpe S; Pepponi I; Walker B; Hokey DA; McShane H; Brennan M; Fletcher H
BMC Infect Dis; 2016 Aug; 16():412. PubMed ID: 27519524
[TBL] [Abstract][Full Text] [Related]
14. A phase I, open-label trial on the safety and immunogenicity of the adjuvanted tuberculosis subunit vaccine H1/IC31® in people living in a TB-endemic area.
Hussein J; Zewdie M; Yamuah L; Bedru A; Abebe M; Dagnew AF; Chanyalew M; Yohannes AG; Ahmed J; Engers H; Doherty TM; Bang P; Kromann I; Hoff ST; Aseffa A
Trials; 2018 Jan; 19(1):24. PubMed ID: 29321075
[TBL] [Abstract][Full Text] [Related]
15. Dose Optimization of H56:IC31 Vaccine for Tuberculosis-Endemic Populations. A Double-Blind, Placebo-controlled, Dose-Selection Trial.
Suliman S; Luabeya AKK; Geldenhuys H; Tameris M; Hoff ST; Shi Z; Tait D; Kromann I; Ruhwald M; Rutkowski KT; Shepherd B; Hokey D; Ginsberg AM; Hanekom WA; Andersen P; Scriba TJ; Hatherill M;
Am J Respir Crit Care Med; 2019 Jan; 199(2):220-231. PubMed ID: 30092143
[TBL] [Abstract][Full Text] [Related]
16. Early cellular immune response to a new candidate mycobacterial vaccine antigen in childhood tuberculosis.
Schepers K; Dirix V; Mouchet F; Verscheure V; Lecher S; Locht C; Mascart F
Vaccine; 2015 Feb; 33(8):1077-83. PubMed ID: 25583385
[TBL] [Abstract][Full Text] [Related]
17. Future Path Toward TB Vaccine Development: Boosting BCG or Re-educating by a New Subunit Vaccine.
Gupta N; Garg S; Vedi S; Kunimoto DY; Kumar R; Agrawal B
Front Immunol; 2018; 9():2371. PubMed ID: 30386336
[TBL] [Abstract][Full Text] [Related]
18. Protection against Mycobacterium tuberculosis infection offered by a new multistage subunit vaccine correlates with increased number of IFN-γ+ IL-2+ CD4+ and IFN-γ+ CD8+ T cells.
Wang X; Zhang J; Liang J; Zhang Y; Teng X; Yuan X; Fan X
PLoS One; 2015; 10(3):e0122560. PubMed ID: 25822536
[TBL] [Abstract][Full Text] [Related]
19. In vitro cellular immune responses to complex and newly defined recombinant antigens of Mycobacterium tuberculosis.
Al-Attiyah R; Mustafa AS; Abal AT; El-Shamy AS; Dalemans W; Skeiky YA
Clin Exp Immunol; 2004 Oct; 138(1):139-44. PubMed ID: 15373916
[TBL] [Abstract][Full Text] [Related]
20. Towards new TB vaccines.
Brazier B; McShane H
Semin Immunopathol; 2020 Jun; 42(3):315-331. PubMed ID: 32189035
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
